Selective Serotonin Reuptake Inhibitors and Suicidality in Juveniles: Review of the Evidence and Implications for Clinical Practice - 18/08/11
Résumé |
This article reviews the existing evidence regarding whether selective serotonin reuptake inhibitors increase suicidal behaviors in children and examines the implications of the findings for clinical practice and research. When balanced against the fact that depression in the young is a serious, recurring condition that produces personal suffering and can lead to suicide, the overall weight of the evidence favors pharmacologic treatment over nontreatment in moderate to severe depression. Nevertheless, the need for careful clinical monitoring of suicidality and attention to behavioral activation, manic switching, and medication compliance or withdrawal are clearly warranted.
Le texte complet de cet article est disponible en PDF.Plan
| Dr. Rey serves on the Australian advisory board for Stratera (Ely Lilly) and Concerta (Janssen Cilag). During the past 5 years, Dr. Martin has received career development support from the National Institute of Mental Health (PHS grant MH 01792), and honoraria, research, or travel support from Alza, Bristol-Myers Squibb, Eli Lilly, and Janssen Pharmaceuticals. |
Vol 15 - N° 1
P. 221-237 - janvier 2006 Retour au numéro
Article précédent
- Female Puberty: Clinical Implications for the Use of Prolactin-Modulating Psychotropics
- Amy L. Becker, C. Neill Epperson
- Teamwork: The Therapeutic Alliance in Pediatric Pharmacotherapy
- Shashank V. Joshi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?